📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-09-30 20:58
206 analysed today
FollowTelegram
206
Today
149,607
All-time analysed
42,901
Positive
6,659
Negative
91,372
Neutral
8,607
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
10 announcements match the current filters (relevance ≥ 5).
Rubfila Shareholders Reject Divestment of Premier Tissues India with 68.01% Votes Against
Rubfila International has disclosed its 33rd AGM voting results, where shareholders decisively rejected the special resolution to ratify the divestment of its entire shareholding in subsidiary Premier Tissues India Limited. Out of 43,47,722 non-interested votes cast on the divestment resolution, 68.01% (29,56,734 votes) voted against, causing the proposal to fail. Meanwhile, ordinary resolutions including the adoption of FY26 financials and a final dividend of Rs 2.00 per share (40%) were approved with over 99.99% majority. The rejection halts the planned exit from the tissue business, which contributed Rs 46.05 Cr to H1 FY26 revenue.
Confidence: HIGH
What changedShareholders blocked the company's proposed divestment of Premier Tissues India Limited at the AGM, while approving the dividend and regular business items.
Why it mattersPremier Tissues is a core growth driver contributing significantly to top-line (Rs 46.05 Cr in H1 FY26); the failed vote stalls the management's capital allocation and restructuring roadmap.
Divestment resolution against vote share: 68.01%Divestment resolution votes against: 29,56,734Final dividend per share: Rs. 2.00Premier Tissues H1 FY26 revenue: INR 46.05 Cr
📅 Short termMarket may react with uncertainty around corporate strategy given the shareholder pushback on the asset sale.
📈 Long termRubfila retains its tissue paper business; management must decide whether to continue investing in Premier Tissues' expansion or propose revised exit terms.
⚠ Risk flags
- Strategic uncertainty regarding capital allocation and future plans for Premier Tissues India
- Shareholder-management misalignment on corporate restructuring
Key Highlights
Special resolution to ratify the divestment of Premier Tissues India Ltd was defeated with 68.01% dissenting votes.
Only 31.99% (13,90,988 votes) of non-interested voting shares supported the divestment resolution.
Shareholders approved a final dividend of Rs 2.00 per equity share of Rs 5 face value (40%).
Adoption of FY26 Standalone and Consolidated Financial Statements passed with 99.9976% assent.
Re-appointment of Director Mr. Hardik B Patel approved with 99.9972% votes in favour.
👀 What to Watch
Track management commentary in upcoming filings regarding their strategic path forward for Premier Tissues India, including whether they intend to retain the subsidiary or renegotiate divestment terms.
Rubfila Holds 33rd AGM; Proposes Divestment of Entire Stake in Premier Tissues India
Rubfila International concluded its 33rd Annual General Meeting on September 29, 2026, where shareholders considered ordinary and special resolutions. Crucially, special business included approval for the divestment of the company's entire shareholding in Premier Tissues India Limited, a subsidiary that contributed Rs 46.05 Cr in H1 FY26. Other items included adoption of FY26 financials and declaration of dividend. E-voting results under Regulation 44 will follow to confirm shareholder approval.
Confidence: HIGH
What changedRubfila held its 33rd AGM and tabled a proposal to completely divest its equity stake in its operating subsidiary Premier Tissues India Limited.
Why it mattersPremier Tissues is a key revenue driver (Rs 46.05 Cr in H1 FY26, targeting 15-20% of consolidated sales). Selling it will refocus Rubfila entirely on its core rubber thread business and generate cash proceeds.
Total shareholders present at AGM: 44Premier Tissues H1 FY26 revenue contribution: Rs 46.05 CrPremier Tissues H1 revenue vs TTM revenue: ~8.1%Divestment consideration/valuation: not disclosed
📅 Short termScrutinizer's voting report will be released within 48 hours to confirm whether the divestment resolution passed.
📈 Long termExiting the tissue business reverses Rubfila's recent diversification strategy, concentrating the company once again purely on heat-resistant latex rubber thread manufacturing and latex price cycles.
⚠ Risk flags
- Loss of revenue diversification away from volatile latex raw material costs.
- Divestment consideration, deal value, and buyer details not yet disclosed.
Key Highlights
AGM held on September 29, 2026, with 44 total shareholders present via video conference (1 promoter, 43 public).
Special resolution proposed for the full divestment of Rubfila's shareholding in subsidiary Premier Tissues India Ltd.
Remote e-voting was conducted from September 26, 2026 (9:00 AM) to September 28, 2026 (5:00 PM).
Resolutions also included adoption of FY26 financial statements and declaration of dividend.
👀 What to Watch
Track the upcoming Regulation 44 voting results disclosure and subsequent announcements detailing the valuation, buyer, and cash consideration for the Premier Tissues divestment.
Rubfila Sets Sep 22, 2026 Record Date for Rs 2/Share Final Dividend (FY26)
Rubfila International has fixed September 22, 2026, as the record date to determine shareholder eligibility for a final dividend of Rs 2 per equity share (face value Rs 5) for FY26. The dividend was originally recommended at the Board meeting held on May 26, 2026. At the current share price of Rs 63.6, the Rs 2 per share dividend represents a dividend yield of approximately 3.14%.
Confidence: HIGH
What changedFormal intimation of the record date (September 22, 2026) for the FY26 final dividend payout.
Why it mattersConfirms the timeline for distributing cash returns to shareholders, reflecting payout on FY26 EPS of Rs 4.89.
Final Dividend per share: Rs.2/-Face Value: Rs.5Record Date: 22-09-2026Dividend to TTM EPS ratio: ~41.9%
📅 Short termStock will trade ex-dividend prior to September 22, 2026, typically adjusting downward by the dividend amount.
📈 Long termLimited; reflects routine annual dividend distribution supported by zero debt and consistent profitability.
Key Highlights
Final dividend declared at Rs 2 per equity share of face value Rs 5 each
Record date fixed for September 22, 2026
Dividend recommended by the Board on May 26, 2026 for FY26
Dividend yield stands at approximately 3.14% based on current market price of Rs 63.6
👀 What to Watch
Investors seeking dividend eligibility must hold shares before the ex-dividend date preceding September 22, 2026; track dispatch/credit timelines post-AGM approval.
Rubfila to divest 100% stake in Premier Tissues for ₹61.00 Cr to promoter-related entity
Rubfila International's Board has approved the complete divestment of its wholly owned subsidiary, Premier Tissues (India) Limited (PTIL), to Finquest Personal Care Pvt. Ltd. for an aggregate cash consideration of ₹61.00 crore. The transaction is a related-party deal, as the purchaser is associated with Rubfila's Chairman, Mr. Hardik Patel, who recused himself from deliberations. For FY26, PTIL contributed ₹95.74 crore (15.68%) to consolidated turnover and ₹51.49 crore (16.59%) to consolidated net worth. The deal consideration of ₹61.00 crore represents ~16.3% of Rubfila's current market cap (₹374 crore), allowing the company to refocus capital on its core rubber-thread business.
Confidence: HIGH
What changedRubfila is fully divesting its tissue paper subsidiary PTIL for ₹61.00 crore to refocus entirely on its core rubber thread operations.
Why it mattersThe sale relieves Rubfila of PTIL's upcoming capex requirements and brings in ₹61.00 crore in cash, but will reduce top-line by ~15.7% going forward.
Sale Consideration: ₹61.00 crorePTIL FY26 Revenue: ₹95.74 crorePTIL Revenue Share: 15.68%PTIL Net Worth Share: 16.59%Consideration vs M-Cap: ~16.3%
📅 Short termShareholder scrutiny is expected around the transaction terms and valuation multiples since the divestment is to a promoter-linked entity.
📈 Long termUnwinds non-core diversification, boosting Rubfila's cash balances and sharpening managerial focus on the heat-resistant latex rubber thread segment.
⚠ Risk flags
- Related-party transaction involving the Chairman/promoter entity requiring minority shareholder approval
- Loss of diversification benefits as PTIL accounted for ~15.7% of consolidated revenue
Key Highlights
100% equity stake in subsidiary Premier Tissues (India) Ltd sold for ₹61.00 crore in cash
PTIL accounted for ₹95.74 crore (15.68%) of FY26 consolidated revenue and ₹51.49 crore (16.59%) of net worth
Transaction is a related-party deal with promoter-entity Finquest Personal Care Pvt. Ltd.
Transaction documents to be executed by September 10, 2026, subject to shareholder approval at AGM on September 29, 2026
Full consideration payable within 30 days of receiving requisite approvals on an 'as is where is' basis
👀 What to Watch
Track minority shareholder voting outcomes on the related-party transaction at the upcoming AGM on September 29, 2026, and watch for subsequent cash inflow updates and deployment plans for the core business.
Rubfila Q1 FY27 PAT Falls 13% YoY to ₹5.8 Cr; Auditor Flags ₹13.8 Cr Contingency Provision
Rubfila International reported a weak start to FY27 with consolidated revenue declining 7.9% YoY to ₹133.49 Cr. Net profit followed suit, dropping 13.3% YoY to ₹5.80 Cr, primarily due to a 12.8% decline in standalone revenue. A significant highlight is the auditor's qualified opinion regarding a ₹13.79 Cr 'Provision for Contingencies' accumulated over 11 years, which the auditors claim does not meet Ind AS 37 criteria for recognition. The tissue subsidiary, Premier Tissues, contributed ₹24.45 Cr to the topline but remains marginally loss-making at the PAT level.
Confidence: HIGH
What changedThe company experienced a YoY contraction in both revenue and profit, while the statutory auditors formally challenged the validity of a long-standing ₹13.79 Cr contingency provision.
Why it mattersThe decline in standalone revenue suggests potential demand or pricing headwinds in the core rubber thread market, while the auditor qualification points to non-standard accounting practices that impact the transparency of the balance sheet.
Consolidated Revenue (Q1 FY27): ₹133.49 CrConsolidated PAT (Q1 FY27): ₹5.80 CrTotal Contingency Provision: ₹13.79 CrSubsidiary Revenue Contribution: ₹24.45 CrRevenue vs TTM Revenue: ~22.1%
📅 Short termThe stock may face pressure due to the double-digit profit decline and the negative auditor remarks regarding accounting compliance.
📈 Long termLong-term value depends on the successful integration and scaling of the tissue business and the company's ability to maintain margins in the rubber thread segment despite volatile latex prices.
⚠ Risk flags
- Auditor qualification on Ind AS 37 compliance
- Loss-making subsidiary operations
- Declining standalone revenue growth
Key Highlights
Consolidated Revenue from operations decreased 7.9% YoY to ₹133.49 Cr from ₹144.93 Cr.
Consolidated Net Profit (PAT) declined 13.3% YoY to ₹5.80 Cr compared to ₹6.69 Cr in the previous year's quarter.
Auditors issued a qualified conclusion regarding an unjustified ₹13.79 Cr provision for contingencies.
Subsidiary Premier Tissues India Limited reported a net loss of ₹18.58 Lakhs on revenue of ₹24.45 Cr.
Standalone revenue, representing the core rubber thread business, fell 12.8% YoY to ₹110.17 Cr.
👀 What to Watch
Investors should monitor the turnaround progress of the tissue subsidiary and watch for management's response to the auditor's qualification regarding the contingency provision, which currently understates equity by ₹13.79 Cr.
Rubfila FY26 Consolidated Revenue Grows 9.5% to ₹602.5 Cr; Recommends ₹2 Dividend
Rubfila International reported a steady performance for FY26 with consolidated revenue reaching ₹60,249.96 Lakhs, up from ₹55,041.28 Lakhs in the previous year. However, consolidated net profit for the full year saw a decline to ₹2,661.19 Lakhs compared to ₹2,943.85 Lakhs in FY25, indicating margin pressure at the group level. Standalone performance was more resilient, with annual net profit rising to ₹2,630.13 Lakhs. The company has rewarded shareholders by recommending a dividend of ₹2.00 per equity share (40% of face value).
Key Highlights
Consolidated annual revenue increased by 9.5% YoY to ₹60,249.96 Lakhs.
Consolidated net profit for FY26 declined to ₹2,661.19 Lakhs from ₹2,943.85 Lakhs in FY25.
Standalone Q4 net profit rose to ₹824.63 Lakhs from ₹768.51 Lakhs in the corresponding quarter of the previous year.
The Board recommended a dividend of ₹2.00 per equity share of face value ₹5/-.
Consolidated Earnings Per Share (EPS) for the full year stood at ₹5.03, down from ₹5.51 in the previous fiscal year.
👀 What to Watch
Investors should monitor the divergence between standalone and consolidated profitability, which suggests underperformance in subsidiaries. The stock remains a hold for dividend-seeking investors given the ₹2 payout.
Rubfila International FY26 Revenue Up 9.5% to ₹602 Cr; Recommends ₹2 Dividend
Rubfila International reported a consolidated revenue growth of 9.5% year-on-year, reaching ₹602.50 crore for the fiscal year ended March 31, 2026. However, consolidated net profit saw a decline of 9.6%, falling to ₹26.61 crore from ₹29.44 crore in the previous year, indicating margin pressure. On a standalone basis, the company performed better with a net profit of ₹26.30 crore compared to ₹24.65 crore in FY25. The Board has recommended a dividend of ₹2.00 per equity share, representing a 40% payout on the face value of ₹5.
Key Highlights
Consolidated annual revenue increased to ₹602.50 crore in FY26 from ₹550.41 crore in FY25.
Consolidated net profit for the year declined to ₹26.61 crore vs ₹29.44 crore YoY.
Standalone Q4 FY26 revenue stood at ₹138.51 crore with a profit of ₹8.25 crore.
Recommended a final dividend of ₹2.00 per equity share for FY26.
Consolidated Earnings Per Share (EPS) decreased to ₹5.03 from ₹5.51 in the previous fiscal.
👀 What to Watch
Investors should note the steady standalone performance but investigate the drag on consolidated profits caused by subsidiaries. The dividend yield remains a positive factor, but margin sustainability in the rubber filaments business needs to be monitored.
Rubfila Q3 FY26 Consolidated Net Profit Drops 31% YoY to ₹5.50 Crore
Rubfila International reported a consolidated revenue of ₹146.73 crore for the quarter ended December 31, 2025, a 6.3% increase year-on-year but a 2.3% decline sequentially. Profitability was significantly impacted, with consolidated net profit falling 30.9% YoY to ₹5.50 crore from ₹7.96 crore. This decline is attributed to rising operational costs, with total expenses increasing to ₹140.94 crore. Standalone performance also weakened, with net profit dropping to ₹4.93 crore compared to ₹6.57 crore in the year-ago period.
Key Highlights
Consolidated Revenue from Operations rose 6.3% YoY to ₹146.73 crore.
Consolidated Net Profit declined sharply by 30.9% YoY to ₹5.50 crore.
Earnings Per Share (EPS) decreased to ₹1.01 from ₹1.47 in the same quarter last year.
Total Consolidated Expenses increased to ₹140.94 crore from ₹128.85 crore YoY.
Nine-month consolidated net profit stands at ₹20.19 crore, down from ₹21.13 crore in the previous year.
👀 What to Watch
Investors should be cautious as the sharp decline in margins suggests rising input costs or operational inefficiencies that are outpacing revenue growth. Monitor the company's ability to pass on costs in upcoming quarters before making new positions.
Rubfila Q3 FY26 Consolidated Net Profit Declines 31% YoY to ₹5.50 Crore
Rubfila International reported a consolidated revenue of ₹146.73 crore for Q3 FY26, a 6.3% increase compared to ₹137.97 crore in the same quarter last year. However, consolidated net profit fell significantly to ₹5.50 crore from ₹7.96 crore YoY, primarily due to rising operational expenses. On a standalone basis, the company saw a sharp sequential decline in profit, dropping 31% from ₹7.16 crore in Q2 FY26 to ₹4.93 crore in Q3 FY26. The nine-month consolidated profit also lags slightly behind the previous year at ₹20.19 crore versus ₹21.13 crore.
Key Highlights
Consolidated Revenue from Operations grew 6.3% YoY to ₹146.73 crore.
Consolidated Net Profit for the quarter dropped 30.8% YoY to ₹5.50 crore.
Standalone Total Expenses increased to ₹116.35 crore from ₹109.67 crore in the year-ago period.
Consolidated Basic EPS decreased to ₹1.01 from ₹1.47 YoY.
Standalone Net Worth improved slightly to ₹281.59 crore as of December 31, 2025.
👀 What to Watch
Investors should be concerned about the margin contraction as revenue growth is not translating into bottom-line gains. It is advisable to wait for signs of raw material cost stabilization before increasing exposure.
Rubfila Q3 FY26 Standalone PAT Drops 24.8% YoY to ₹4.93 Cr Despite Revenue Growth
Rubfila International reported a weak bottom-line performance for Q3 FY26, with standalone Net Profit falling 24.8% YoY to ₹4.93 crore. While standalone revenue saw a modest growth of 3.8% YoY to ₹121.61 crore, it declined 5.1% on a sequential basis compared to Q2 FY26. Profitability was significantly impacted by rising operational costs, leading to a drop in EPS from ₹1.21 to ₹0.91. On a consolidated basis, the profit decline was even steeper at 30.8% YoY, indicating pressure across the group's operations.
Key Highlights
Standalone Revenue from Operations increased 3.8% YoY to ₹12,161.10 lakhs.
Standalone Net Profit (PAT) declined 24.8% YoY to ₹493.39 lakhs from ₹656.58 lakhs.
Consolidated Q3 PAT fell sharply by 30.8% YoY to ₹550.32 lakhs.
Standalone EPS for the quarter stood at ₹0.91, down from ₹1.21 in the same period last year.
Total standalone expenses for the quarter rose to ₹11,634.69 lakhs compared to ₹10,966.70 lakhs YoY.
👀 What to Watch
Investors should monitor the company's margin profile closely as rising costs are eroding profitability despite stable revenues. The sequential decline in both revenue and profit suggests a challenging near-term environment for the rubber filament segment.
